vcfirmsdirectory.com

Venture capital · Early stage

Frazier Life Sciences

Frazier Life Sciences is a healthcare-focused investment firm running venture and public equity strategies that back and build companies developing novel therapeutics. It has offices in Palo Alto, San Diego, Boston and Seattle.

Palo Alto · San Diego · Boston · SeattleRegistered · Palo Alto
New investments · 12 months
Fund vehiclesPublic
6
6 active · US private fund
First cheque
Active portfolio
FreeRegistry entries, fund vehicles and filingsPROEverything we enrich: deals, team, events and signals
Updated 25 Oct 2026, 02:04 CETSources: frazierls.com · SEC adviser filings

Investment activity

Round-by-round activity is part of PRO

See every round Frazier Life Sciences joined

Monthly deal flow, follow-ons, fund closes and exits.

Key signal this week

See all signals

Is Frazier Life Sciences right for your round?

Is Frazier Life Sciences a fit for your round?

Match your sector, round, size and region against where they invest, and see who to approach.

Key stats

Fund vehiclesPublic
6
6 active · US private fund
SEC adviser filings
First cheque
Core stage
New deals per year
Lead rate
Active portfolio
Exits

Fund cycle Public record

Fund vehicles on public registers (SEC adviser filings). Values are the gross assets each filing reports, not fund sizes.

FRAZIER LIFE SCIENCES PUBLIC FUND, L.P.US private fund · Active · United States · $2.9B gross assets · filed 31 Mar 2026
FRAZIER LIFE SCIENCES XII, L.P.US private fund · Active · United States · $1.4B gross assets · filed 31 Mar 2026
FRAZIER LIFE SCIENCES XI, L.P.US private fund · Active · United States · $1.1B gross assets · filed 31 Mar 2026
FRAZIER LIFE SCIENCES X, L.P.US private fund · Active · United States · $781.2M gross assets · filed 31 Mar 2026
FRAZIER LIFE SCIENCES IX, L.P.US private fund · Active · United States · $596.5M gross assets · filed 31 Mar 2026
FRAZIER LIFE SCIENCES VIII, L.P.US private fund · Active · United States · $260.2M gross assets · filed 31 Mar 2026
Deployed (new cheques)
Next fund expected

Latest investments

BetaRounds Frazier Life Sciences joined, from press and the firm’s own posts.

DateCompanyRoundRound sizeRoleAlongside

3 rounds in the last 12 months

Round sizes, Frazier Life Sciences’s role and who invested alongside.

Round-by-round history is part of PRO

Notable portfolio

35PharmaAcerta PharmaAchaogenAdverum BiotechnologiesAirnexis TherapeuticsAkero TherapeuticsAlcresta TherapeuticsAlentis TherapeuticsAlesta TherapeuticsAllena Pharmaceuticalsand 40 more

Portfolio and exits

Every company Frazier Life Sciences backed and how the exits played out.

Where the money goes

Share of companies at first investment, from the rounds we track.

Where Frazier Life Sciences puts its money

Sector, country and stage mix across every first cheque.

Investment team

The investment team

Partners, principals and investors, with their city, focus and how to reach them.

Where to meet Frazier Life Sciences

Events where Frazier Life Sciences’s team spoke or showed up, from event programmes, press and the firm’s own posts.

Where to meet Frazier Life Sciences’s partners

The events they speak at, your next chance to meet them, and which ones founders can get into.

Signals

Register and fund filings are free. Website, team and portfolio changes we pick up are PRO.

24 Jun 2026New deal
18 Jun 2026New deal
31 Mar 2026Fund filingForm ADV filed by FRAZIER LIFE SCIENCES MANAGEMENT, LP: 6 private funds, $7B in gross assets.SEC Form ADV · public record
20 Nov 2025New deal
12 Nov 2024New deal

Founders also look at

Frequently asked questions

Frazier Life Sciences is based in Palo Alto, United States. It also has offices in San Diego, Boston and Seattle.

6 fund vehicles are on public registers (SEC adviser filings), including FRAZIER LIFE SCIENCES PUBLIC FUND, L.P., FRAZIER LIFE SCIENCES XII, L.P. and FRAZIER LIFE SCIENCES XI, L.P.

Stages: Series A. Sectors: Biotech, Life sciences. From the firm’s own website.

Invests in and builds product-focused biopharma companies able to produce meaningful clinical data or commercialize therapeutics. Venture strategy emphasizes company creation and Series A, preclinical-to-clinical, with significant equity ownership and long-term management partnerships. Public strategy is long-only, evergreen, covering listed small/mid-caps and crossover rounds. From the firm’s own website.

Frazier Life Sciences lists 50 portfolio companies on its website, including 35Pharma, Acerta Pharma, Achaogen, Adverum Biotechnologies and Airnexis Therapeutics.

Firms whose websites list some of the same companies include Longitude Capital, RA Capital and Alta Partners.

Know before Frazier Life Sciences’s next round is announced.

PRO tracks Frazier Life Sciences’s filings, hires and portfolio changes the day they land, alongside 3,869 other firms.

Frazier Life SciencesGet Frazier Life Sciences’s signals the day they landMonitor

Search the directory

Type a firm's name, a city or a country.